Cabotegravir for HIV-exposed newborns

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study in Phase 1/2 evaluates the safety, tolerability, and how the drug behaves in the body (pharmacokinetics) of cabotegravir given as oral and injectable long-acting formulations to neonates exposed to HIV-1. Eligible infants are full-term or near-term, under 10 days old, with a birth weight of at least 2 kg, and whose mothers are on a dolutegravir-based regimen and plan to breastfeed. All participants have started standard HIV prophylaxis at entry and are assessed by site investigators for overall health. The trial is led by ViiV Healthcare with locations at GSK Investigational Sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 37 weeks gestation at delivery.
* \<=10 days of life.
* Birth weight at least 2 kg.
* At Entry, neonate has initiated standard of care Antiretroviral drug (ARV) prophylaxis.
* At Entry, neonate is generally healthy as determined by the site Investigator based on review of all available medical history information and physical examination findings.
* Mother is on a Dolutegravir (DTG) based regimen for a minimum of 4 weeks prior to delivery, regardless of maternal viral load.
* Mother is currently breastfeeding or plans to breastfeed infant.
* Mother is of legal age or circumstance to provide independent informed consent and is willing and able to provide documented informed consent for her and her infant's participation in this study.
* Mother has confirmed HIV-1 infection based on positive test results from 2 samples collected from 2 separate blood samples. Test results may be obtained from medical records or from testing performed during the study Screening period.

Exclusion Criteria:

Medical conditions

* Severe congenital malformation or other medical condition not compatible with life or that would interfere with study participation or interpretation, as judged by examining clinician.
* Known maternal-fetal blood group incompatibility which can result in hemolytic disease of the newborn.
* Known family history of G6PD deficiency.
* Prior/Concomitant therapy
* Mother who has previously received, is receiving, or will be receiving CAB post-partum.
* Neonate or breastfeeding mother is receiving any disallowed medication.
* Prior/Concurrent clinical study participation
* Neonate has exposure to other investigational drugs that might interfere with study intervention metabolism.
* Diagnostic assessments
* Mother has known Integrase strand transfer inhibitor (InSTI) resistance.
* At Entry, neonate with a confirmed, documented positive HIV Nucleic acid amplification test (NAAT) test result.
* At Screening, neonate has any of the following laboratory test results:

  * Alanine transaminase or Aspartate aminotransferase of more than 2.5 x Upper limit of normal (ULN).
  * Total bilirubin in range for phototherapy at Entry.
  * Hemoglobin \<13.0 g/dL.
  * Decreased white blood cells Grade 3 or above.
  * Platelets \<50 000 cells/mm3
  * Creatinine value more than 1.3 the ULN for postnatal age as defined in Division of AIDS (DAIDS)
  * Albumin Grade 3 or higher.
  * Direct bilirubin Grade 3 and above.
* Any other Grade ≥3 event on DAIDS toxicity table
* Neonates with prior exchange transfusion. Other exclusion criteria
* Mother or neonate has a condition that, in the site Investigator or designee's opinion, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
* Neonate is receiving DTG as part of HIV prophylactic regimen. Liver safety exclusion criteria
* Known maternal hepatitis B infection. Cardiac safety exclusion criteria
* At screening, QT interval corrected using Fridericia's formula \>450 msec.

Where it's running

• GSK Investigational Site
  Parow Valley, South Africa Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.